MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Biotechnology_Personalized, Precision, Preemptive Medicines
NexImmune, Inc. (NASDAQ: NEXI)
Organization & Developments: NexImmune
Parents
NexImmune, Inc. (NASDAQ: NEXI)
Children
*NexImmune is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body's own T cells to generate a specific, potent and durable immune response
*NexImmune's precision technology, broad platform, and unique approach to immunotherapy address difficult-to-treat cancers and immune-mediated disease
2012: Maryland stem cell companies advance therapies for diabetes, depression (2012)
2012: NexImmune announced that it has licensed from Johns Hopkins the Artificial IMmune nanotechnology developed by Schneck and a colleague, Mathias Oelke.
2023: NexImmune Reports Third Quarter 2022 Financial Results and Announces Strategic Update_ neximmune
2023: NexImmune to lay off 53% of employees to save money, CFO to step down _ endpts
Jumps
*Key People: NexImmune
Finance & Acquisition: NexImmune